Ann D. Rhoads, an insider at QuidelOrtho Corp (QDEL), acquired 15,021 shares of the company's stock on December 9, 2025, at a price of $28.27 per share, totaling approximately $425,000. Following this transaction, Rhoads holds a total of 15,021 shares in the company.
This purchase may signal confidence in QuidelOrtho's future, as insiders often have access to non-public information regarding their company's performance. However, investors should be cautious; insider transactions can stem from personal or regulatory motivations, and should not be the sole factor in investment decisions.
QuidelOrtho operates in the health care sector, specializing in vitro diagnostics. The company, headquartered in San Diego, California, employs around 6,600 full-time staff and provides a range of diagnostic solutions across various business units, including labs, molecular diagnostics, point of care, and transfusion medicine.
As of November 8, 2025, QuidelOrtho's market capitalization stands at $1.4 billion, with a trailing twelve-month earnings per share (EPS) of -6.90. Upcoming earnings reports are scheduled for May 5, 2026, with an EPS estimate of $0.84 and revenue projected at $724.8 million, followed by another report on August 3, 2026, with an EPS estimate of $0.22 and revenue of $645.3 million.
Insider transactions are publicly reported to the SEC, providing transparency into executives' views on their company's stock. However, investors should consider patterns of activity across multiple insiders and timeframes for a more comprehensive evaluation of these signals.